A Comparison of 141W94 and Indinavir in HIV-Infected Patients

Inclusion Criteria Patients must have: * Documented HIV infection. * HIV RNA \>= 400 copies/ml within 14 days prior to randomized study drug administration. * No active AIDS-defining opportunistic infection or disease. * Signed, informed consent from parent or legal guardian of patients less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Unlikely to complete the randomized dosing period. * Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption or ability to take oral medications. * Serious medical conditions (e.g., diabetes, cardiac dysfunction, hepatitis) that would compromise patient safety. Concurrent Medication: Excluded: * Cytotoxic chemotherapeutic agents (except local treatment for Kaposi's sarcoma). * Investigational treatments (treatment through Treatment IND or expanded-access programs are evaluated individually). * Immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons. * Terfenadine, astemizole, cisapride, triazolam, midazolam, and ergotamine/dihydroergotamine-containing regimens. Concurrent Treatment: Excluded: Radiation therapy (except local treatment for Kaposi's sarcoma). Patients with the following prior conditions are excluded: Clinically relevant pancreatitis or hepatitis within the last 6 months. Prior Medication: Excluded: * Cytotoxic chemotherapeutic agents within 30 days of study drug administration (except local treatment for Kaposi's sarcoma). * Protease inhibitor therapy. * Dose of vaccine through an investigational HIV vaccine trial within the 3 months prior to study drug administration. * Immunomodulating agents such as systemic, high-dose corticosteroids, interleukins, or interferons within 30 days of study drug administration. Prior Treatment: Excluded: Radiation therapy within 30 days prior to study drug administration (except local treatment for Kaposi's sarcoma). Risk Behavior: Excluded: Current alcohol or illicit drug use that may interfere with drug absorption or ability to take oral medication. Required: NRTI therapy at day of entry and up to screening. Required: \>= 12 weeks of NRTI therapy.